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Abstract. The belief that following rigorous inclusive methods will eliminate bias 
from ‘quality’ measures ignores the preferences necessarily embedded in any 
formative instrument. These preferences almost always reflect the interests of its 
developers when one uses the wide definition of ‘interest’ appropriate in 
healthcare research and provision. We focus on the International Patient Decision 
Aid Standards instrument, a popular normative measure of decision aid quality. 
Drawing on its application to a set of 23 breast cancer screening decision aids, we 
show the effects of modifications that reflect our own different interest-conflicted 
preferences. It is emphasised that the only objection is to the implication that any 
formative instrument should be promoted or treated as the ‘the gold standard’, 
without a conflict of interests disclaimer, and to the implication that other 
instruments cannot provide equally valid, high-quality measures. 
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1. Introduction 
There is growing agreement that the future will be dominated by the social and self-
production of health by citizens, optionally supplemented by its co-creation with 
healthcare professionals. This means that the provision of apomediative decision 
support direct to the person in the community is of increasing relevance and 
importance, in addition to intermediative decision support direct from the clinician to 
the citizen-as-patient. For clarity we will refer to the former as apomediative Person 
Decision Support Tools (PnDSTs) and the latter as intermediative Patient Decision 
Aids (PtDAs). The terms ‘intermediative’ and ‘apomediative’ are those of Eysenbach 
[1] and characterise, respectively, the presence or absence of a dependent relationship 
between the supplier of the support and the professional involved in the decision. 
Despite this distinction the quality of both types must be assessed appropriately, 
and this includes addressing possible bias. Unfortunately, the belief that by following 
rigorous ‘scientific’ methods, all biases can be eliminated, involves confusing whether 
they are seen as acceptable, justifiable, or desirable, with their inevitability. This 
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inevitability is at its clearest in indexes developed to measure the quality of some state 
(e.g. of health), of some action (e.g. of surgery), of some process (e.g. shared decision 
making), or of some intervention (e.g. a decision aid or support tool). All quality 
indexes are formative measures and therefore dependent on the preferences - the value 
judgments - involved in (a) the selection of the component scales (instrument items) 
and (b) the weighting of those selected scales to form a quality index. Evaluations 
using such quality measures are therefore ‘preference-sensitive’ [2] and, given 
preferences are rarely in conflict with interests, they are usually biased in the sense of 
‘interest-conflicted’. 
The definition of ‘interest’ used here is the wide one we regard as relevant in 
healthcare, including research and provision, not a narrow legal/financial one that 
ignores the serious conflicts arising for a variety of institutional and personal reasons 
[3]. Among these interests are the ones listed in the first section of Rodwin’s typology: 
Intellectual commitments (e.g. working within a theoretical framework, school of 
thought, or having proposed a hypothesis). Interest in a positive outcome to a study that 
will support your previous findings. Interest in maintaining professional reputation. 
Interest in career advancement. Interest in finding potential practical applications of 
research. Interest in maintaining good relations with entities that can provide future 
research funding [4]. 
With this wider definition of interest - particularly the inclusion of commitments to 
theoretical frameworks or schools of thought - the first issue is not whether a quality 
measure is ‘interest-conflicted’, but the nature and origins of the interest-conflicted 
preferences that are necessarily reflected in its development. Whether or not these 
interests are regarded by some (many) as acceptable or desirable, the second, but 
equally important issue, is the attitude and behaviour of those responsible towards 
alternative measures, which, by definition, also reflect interest-conflicted preferences. 
Quality being a formative construct, any alternative is a measure of a different 
construct (e.g. of decision aid quality), not an alternative measure of the same one. 
The wide range of interests underlying the preferences reflected in a formative 
measure should therefore be declared alongside any legal requirement, accompanied by 
a denial of any intention to seek to establish the measure as ‘the gold standard’, with an 
effective monopoly on professional endorsement and regulatory approval. An example 
of good behaviour is provided by the generic health-related quality of life measures, 
where alternatives co-exist in friendly, if robust, rivalry. 
In this first of two papers we focus on the normative measurement of the quality of 
decision aids, in other words on measures which consider only the content of the aid 
and/or its development process. In the companion paper [5], we see how the argument 
applies in the empirical measurement of decision aid quality, as implemented. In both 
we focus on the products of the International Patient Decision Aid Standards (IPDAS) 
consortium, but it is important to see that the argument is completely generic.  
We take the International Patient Decision Aid Standards instrument (IPDASi) as 
our specific focus [6]. It should already have been inferred that we will not be 
‘criticising’ or even ‘critiquing’ IPDASi from some purportedly neutral, unbiased 
(interest-unconflicted) position. We will be pointing out the way the preferences and 
interests it reflects do not coincide with our own, and arguing why it should not be 
promoted and/or treated as the ‘gold standard’, as opposed to a standard based on a 
widely-agreed, but particular, set of preferences and interests. The setting of an IPDASi 
standard for decision aid ‘certification’ [7] is not in itself objectionable, only any 
implication or inference that aids that do not meet this certification standard should not 
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be regarded as usable for this reason alone. To repeat, this is a widespread 
phenomenon and the same danger can be detected with other quality measures [8,9]. 
To give the argument empirical flesh we draw on the recent paper by Hild and 
colleagues [10]. They assessed the quality of 23 decision aids for women at average 
risk of breast cancer (and eligible for mammographic screening) using the original 
IPDAS 47 item instrument. We take advantage of the complete data set they provided 
to see the effects of modifying the instrument to reflect our different preferences. 
2. Modifying IPDASi 
Our preferences are fully in agreement with IPDASi in distinguishing conceptually 
between binary checklist items and scalar index items. The former must be met. The 
latter may be only partially fulfilled and, most importantly, are compensable - lower 
ratings on some may be countered by higher ratings on others. IPDASi recognise this 
distinction in partitioning their later 44 item version into three parts [7] with a 
certification sub-set. 
Six binary qualifying (checklist) items are ones to be met for something to qualify 
as a decision aid: “1) the intervention should relate to a specific decision that has to be 
made; 2) patients should be helped to choose deliberately among options; 3) positive 
and negative features of the options should be presented; 4) outcomes given should be 
relevant to health status; 5) the intervention should not promote compliance with a 
recommended option; and 6) the intervention should help patients to clarify values.” 
Ten certification criteria, scored on a 1–4 scale (‘strongly disagree’ to ‘strongly 
agree’), are “deemed essential in order to avoid risk of harmful bias… Decision aids 
must meet all of these criteria to be certified. The 6 certification criteria selected relate 
to the quality of the evidence synthesis process, open disclosure of funding source, and 
a balanced presentation of options, with 4 additional items for screening/test aids.” 
Twenty-eight quality items are deemed “desirable because they would enhance a 
decision aid but are not essential for reducing risk of harmful bias… These items would 
improve the experience of using the decision aid, but absence of the item would not be 
expected to influence the individual’s decision in a negative way.” 
Tools should meet all qualifying criteria and score 3 or 4 on each of the 10 
certification criteria in order to reach the certification standard. (Hild, et al. do not cite 
the 2013 paper in which this item classification and certification standard is introduced 
and hence make no reference to certification in their analysis.) 
Our preferences would reduce the IPDASi list from 44 to just 5 items. We retain 
the IPDASi wording here, as sufficient for the present purpose. 
1. The aid makes it possible to compare the positive and negative features of the 
available options.  
2. The aid provides information about outcome probabilities associated with the 
options (i.e. the likely consequences of decisions)  
3. The aid asks patients to think about which positive and negative features of the 
options matter most to them (implicitly or explicitly). 
4. The aid (or associated documentation) describes how research evidence was 
selected or synthesized 
5. The aid was field tested with patients who were facing the decision 
All 5 of these fall only in the residual ‘quality’ category for IPDASi, in other words 
none are required for certification. It follows we must regard their 10 certification items 
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as either merely ones necessary for acceptance as an aid (we indeed regard 5 of them as 
‘qualifiers’), or as redundant (the other 5 certifying items, including all the screening 
test ones, are indeed covered in item 2 above if this is fulfilled properly. Spelling them 
out as separate items either implies that item 2 is not required to be fulfilled properly, 
or involves double counting. (There is a major omission in the IPDASi test set in our 
view. The prior odds of the target condition are essential in decision support, 
prevalence being the usual proxy. Providing only the True and False Positive and 
Negative rates, as IPDASi requires, is likely to be misleading if the user cannot also see 
the False Alarm and False Reassurance Rates. These appear in item 2 if done properly.) 
The correlation between the scores on our 5 item selection and the Hild 47 items 
scores is 0.89, confirming the feasibility of serious reduction. But the correlation with 
the certification items is only 0.66, confirming that preferences make a major 
difference. Applying the certification standard (rated 3 or 4), to our 5 items, only 3 of 
the 23 aids are certifiable. In contrast to IPDASi our preferences would certify the 
Schonberg aid, which fails IPDASi by not providing an update policy and not 
indicating the next steps if the target condition is not detected. (The latter is a 
redundant item for us.) Contrariwise, we would not certify the Keevil aid, because it is 
not describing well enough ‘how research evidence was selected or synthesized’. (The 
analysis is at http://bit.ly/hildanalysis, but the argument does not depend on its details.) 
3. Interest-Conflicted Preferences 
Where and how do interests come in? First, in the inclusion of process criteria 
regarding the development process, criteria made redundant for us by rigorous testing 
using outcome criteria. If this testing is conducted properly, we see no justification for 
using any aspect of the development process (including the credentials of the people 
involved in it) in establishing the quality of an aid.  
Second, through the omission of items that preserve the interests of healthcare 
professionals in not having to deal with a preliminary opinion based on numerical 
analytic calculation, as opposed to one designed to fit a verbal deliberative reasoning 
process. Items 2 and 3, when fulfilled according to our preferences, provide all the 
ingredients necessary to calculate the expected value of each option, using the 
importance weights of the person. Calculating and displaying those scores is absent 
from IPDASi, whereas it is the central feature of aids based on other techniques. 
Third, through preference specification. Our preference is for decision support 
tools that are preference-sensitive at the point of care. These cannot be based on group 
average tariffs, let alone be those of a panel whose expertise and eminence relate to 
belief judgments about option performance rates, not value judgements about those 
criteria. In the online spreadsheet we enable the preference-sensitive weighting of the 
47 items IPDASi set. To illustrate, we assign weight to only our 5 preferred items. The 
reader is free to explore alternative weights. 
4. Conclusion 
That IPDASi was built by a large international consortium in a prolonged and rigorous 
Delphi process gives it unquestioned credibility and the right to have aids promote 
themselves as being ‘certified by the IPDASi standard’. But implying that it is a ‘gold 
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standard’ and that an aid that fails to meet it cannot, by that fact, be a valid, possibly 
excellent, decision aid, conflicts with the scientific standards its developers - and the 
informatics community - would undoubtedly wish to uphold. The same applies to all 
alternative measures of decision support quality and indeed to all quality metrics. 
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